Generic semaglutide goes on sale in India at up to 80% below Novo Nordisk prices

Generic versions of semaglutide went on sale in India over the weekend, after Novo Nordisk's patent on the molecule expired there on March 20 ^[1]. At least five Indian manufacturers are selling copies at up to 80% below the brand-name price, and more than 50 generic brands are expected to reach the market in the coming months ^[1].

What the generics cost

Sun Pharmaceutical launched a generic semaglutide for as little as 750 rupees (about $8) for a weekly injection, or roughly 3,400 rupees a month, against Novo's retail price of 8,800 to 10,000 rupees depending on dose ^[1]. Dr. Reddy's Laboratories began selling a version for type 2 diabetes at about 4,200 rupees a month and plans to expand to Canada, Turkey and Brazil this year. It is targeting 12 million semaglutide pens in the first year across all markets ^[1].

Smaller, domestic-focused manufacturers are going lower. CNBC reported Natco Pharma's vial formulation at 1,250 rupees a month, among the most affordable options on the market ^[1]. A separate account lists the Natco vial at 1,290 rupees for the 2 mg/1.5 ml and 4 mg/3 ml strengths and 1,750 rupees for the 8 mg/3 ml strength ^[2]. Alkem Laboratories introduced prefilled injections starting at 1,800 rupees a month ^[1]. Zydus Lifesciences is selling a reusable multi-dose pen at about 2,200 rupees a month, and Glenmark's GLIPIQ falls in the 1,300 to 1,760 rupee range ^[2].

Branded semaglutide sold for about 10,850 to 16,400 rupees a month before the patent expired, after Novo cut prices by up to 37% ^[2]. CNBC reported that cut came in December, while the other account dates it to November 2025 ^[1][2].

How Novo is defending its position

Novo has cut prices and leaned on partnerships. Wegovy is being launched in India as Poviztra with Emcure Pharma, while Ozempic is marketed as Extensior with Abbott India ^[1]. Vikrant Shrotriya, managing director of Novo Nordisk India, said the company's "size, technology, and complete care ecosystem justify the price we are getting after a 37% reduction" ^[1].

Analysts gave mixed views. Vishal Manchanda of Systematix Group said Novo could keep a large share of the market if it holds a 15% to 20% premium over generics ^[1]. Sydbank's Søren Løntoft Hansen said generics will affect Novo's India sales, but it is not yet clear whether the company will lose its leading position. Jyske Bank's Henrik Hallengreen Laustsen said that if semaglutide is sold only in countries where patents have expired, Novo would be able to maintain its market dominance ^[1].

Sales of GLP-1 drugs in India rose 178% from a year earlier in February, reaching 14.46 billion rupees in moving annual turnover, according to the market intelligence firm Pharmarack ^[1]. India has about 100 million people living with diabetes and nearly a quarter of its population classified as obese ^[1]. Diabetes specialist Rajiv Kovil said nearly 50% of his patients could benefit from GLP-1 drugs, but only about 5% are using them ^[1].

Why it matters for patients

Semaglutide remains protected by patents in the United States until 2032, so these Indian generics are not authorized for the U.S. market, and no change to U.S. availability or pricing has been reported ^[1][2]. The U.S. is Novo's largest market by far ^[1].

There is also concern that low-cost semaglutide made at scale in India could reach countries where patents are still in force. "If India is starting to manufacture GLP-1s at a large scale, that will not all stay in India, whatever companies try, countries try to prevent it from coming in," said Ben van der Schaaf, a partner at Arthur D. Little ^[1].

Semaglutide is a peptide drug that needs cold-chain storage and strict quality controls. Knud Jensen, a chemistry professor at the University of Copenhagen, said the molecule given to patients "has to be perfect, and it cannot have any side products or contaminants" ^[1]. Counterfeits are a persistent feature of injectable categories in India, according to one account ^[2]. Whether any Indian manufacturer will seek U.S. approval for a generic semaglutide, and on what timeline, has not been disclosed ^[1].

What happens next

Dr. Reddy's plans to sell its semaglutide in Canada, Turkey and Brazil this year ^[1]. Semaglutide patents also expire in Canada, Brazil and China in 2026 ^[1]. Canada and Brazil together account for nearly $2 billion in annual branded semaglutide sales ^[2]. Novo warned in February that its 2026 sales could decline by 5% to 13% ^[1], and there is no official indication from Novo or Eli Lilly about a fresh round of price cuts ^[1].